Cargando…

Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis

Detalles Bibliográficos
Autores principales:	Sara, De Sanctis, Luciana, Breda, Marianna, Del Torto, Manuela, Nozzi, Marta, Lucantoni, Marianna, Sebastiani, Angelika, Mohn, Francesco, Chiarelli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194523/ http://dx.doi.org/10.1186/1546-0096-9-S1-P169

Ejemplares similares

Autoinflammatory syndromes: diagnosis and management
por: De Sanctis, Sara, et al.
Publicado: (2010)

Preliminary data on insulin sensitivity in non-obese prepubertal children affected by juvenile idiopathic arthritis
por: Luciana, Breda, et al.
Publicado: (2011)

TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?
por: Scardapane, A., et al.
Publicado: (2012)

Association between inflammatory status and intima-media-thickness in children with juvenile idiopathic arthritis: preliminary data
por: Breda, L, et al.
Publicado: (2008)

PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis
por: Kaleda, MI, et al.
Publicado: (2013)

Juvenile/Adolescent Idiopatic Scoliosis and Rapid Palatal Expansion. A Pilot Study
por: Piancino, Maria Grazia, et al.
Publicado: (2021)

Growth Abnormalities in Children with Type 1 Diabetes, Juvenile Chronic Arthritis, and Asthma
por: Giannini, Cosimo, et al.
Publicado: (2014)

The sagital balance in idiopatic and neuromuscular scoliosis
por: Borges, Paulo Alvim, et al.
Publicado: (2014)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

Growth and puberty in children with juvenile idiopathic arthritis
por: d’Angelo, Debora Mariarita, et al.
Publicado: (2021)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
por: Verazza, Sara, et al.
Publicado: (2014)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
por: Öman, Anders, et al.
Publicado: (2021)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Genetic Background and Molecular Mechanisms of Juvenile Idiopathic Arthritis
por: La Bella, Saverio, et al.
Publicado: (2023)

Could Chronic Idiopatic Intestinal Pseudo-Obstruction Be Related to Viral Infections?
por: Sinagra, Emanuele, et al.
Publicado: (2021)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Kidney function and renal resistive index in children with juvenile idiopathic arthritis
por: Cafarotti, Alessandro, et al.
Publicado: (2022)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
por: Foeldvari, Ivan, et al.
Publicado: (2019)

Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report
por: Marsili, Manuela, et al.
Publicado: (2016)

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
por: Horneff, Gerd, et al.
Publicado: (2014)

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
por: Verazza, Sara, et al.
Publicado: (2016)

Long-term outcome after Boston brace treatment in adolescent idiopatic scoliosis
por: Lange, JE, et al.
Publicado: (2009)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_quo0phbg4v73irmkscacip71l3